查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878872

婦科藥物市場－全球產業規模、佔有率、趨勢、機會和預測，依治療方法、適應症、配銷通路、地區和競爭格局分類，2020-2030年預測

Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Indication, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球婦科藥物市場規模為62億美元，預計2030年將以7.78%的複合年成長率成長至97.2億美元。婦科藥物是指用於診斷、治療或預防女性生殖系統疾病的藥物，涵蓋從月經不規則、不孕症到婦科癌症和更年期症狀等一系列疾病。推動市場擴張的主要因素包括：子宮內膜異位症和多囊性卵巢症候群等婦科疾病在全球範圍內的盛行率不斷上升，以及人們對女性健康的日益重視和積極主動的管理方式。

市場概覽
預測期 2026-2030
2024年市場規模 62億美元
2030年市場規模 97.2億美元
2025-2030年複合年成長率 7.78%
成長最快的細分市場 荷爾蒙療法
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球婦科藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療方法（非荷爾蒙療法、荷爾蒙療法）分類
    • 依適應症（避孕、婦科感染、女性不孕症、停經後疾病、多囊性卵巢症候群、骨質疏鬆症、婦科癌症、子宮內膜異位症、其他）
    • 按配銷通路（零售藥局、醫院藥局、網路藥局）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美婦科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲婦科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太婦科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲婦科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美婦科藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球婦科藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Amgen Inc.
  • Novartis AG
  • Bayer AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc
  • Lupin Limited

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 7427

The Global Gynecology Drugs Market, valued at USD 6.20 Billion in 2024, is projected to experience a CAGR of 7.78% to reach USD 9.72 Billion by 2030. Gynecology drugs are pharmaceutical agents developed to diagnose, treat, or prevent conditions specific to the female reproductive system, encompassing a range of disorders from menstrual irregularities and infertility to gynecological cancers and menopausal symptoms. The market's expansion is fundamentally supported by several drivers, including the escalating global prevalence of gynecological disorders such as endometriosis and polycystic ovary syndrome, alongside a heightened awareness and proactive approach to women's health.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.20 Billion
Market Size 2030USD 9.72 Billion
CAGR 2025-20307.78%
Fastest Growing SegmentHormonal Therapy
Largest MarketNorth America

Key Market Drivers

The global gynecology drugs market experiences substantial expansion driven by the rising prevalence of gynecological disorders worldwide. Conditions such as endometriosis, polycystic ovary syndrome, and uterine fibroids affect a significant portion of the female population, creating an imperative demand for effective pharmaceutical interventions. This increasing disease burden necessitates ongoing research and development into novel therapeutic solutions to manage symptoms, improve quality of life, and address underlying pathologies. According to the World Health Organization, in March 2023, endometriosis alone impacts approximately 10 percent, or 190 million, of reproductive age women and girls globally, highlighting the widespread need for treatments. This pervasive presence of gynecological ailments underpins the consistent requirement for diagnostic and treatment drugs, forming a fundamental driver for market growth.

Key Market Challenges

The substantial cost associated with developing and obtaining regulatory approval for novel gynecological therapeutics presents a significant impediment to the growth of the Global Gynecology Drugs Market. The extensive research and development (R&D) phases, coupled with the rigorous and often protracted regulatory pathways, necessitate considerable financial outlays. This elevated expenditure increases the financial risk for pharmaceutical companies, particularly when considering specific gynecological conditions that may affect smaller patient populations or require highly specialized, complex therapeutic approaches.

Key Market Trends

This trend fundamentally transforms the development and application of gynecological drugs by tailoring treatments to individual patient genetic profiles and disease characteristics. This precision approach allows for more effective interventions with reduced side effects, moving beyond traditional broad-spectrum pharmaceuticals. The market emphasizes identifying specific biomarkers that predict drug response or disease progression, particularly in gynecologic oncology. Venture capital funding in women's health recorded a single-quarter high of $435 million in the third quarter of 2023, according to a Silicon Valley Bank report, indicating robust financial backing for specialized therapeutic advancements. This drives the development of novel diagnostics and companion therapies, leading to more targeted options for patients.

Key Market Players

  • Amgen Inc.
  • Novartis AG
  • Bayer AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc
  • Lupin Limited

Report Scope:

In this report, the Global Gynecology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gynecology Drugs Market, By Therapeutics:

  • Non-Hormonal Therapy
  • Hormonal Therapy

Gynecology Drugs Market, By Indication:

  • Contraception
  • Gynecology Infections
  • Female Infertility
  • Postmenopausal disorders
  • Polycystic Ovary Syndrome
  • Osteoporosis
  • Gynecology Cancer
  • Endometriosis
  • Others

Gynecology Drugs Market, By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Gynecology Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gynecology Drugs Market.

Available Customizations:

Global Gynecology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gynecology Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutics (Non-Hormonal Therapy, Hormonal Therapy)
    • 5.2.2. By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others)
    • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Gynecology Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gynecology Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutics
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Gynecology Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutics
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Gynecology Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutics
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Distribution Channel

7. Europe Gynecology Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gynecology Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Gynecology Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Gynecology Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Gynecology Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutics
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Gynecology Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutics
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Gynecology Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gynecology Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Gynecology Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Gynecology Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Gynecology Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Gynecology Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Gynecology Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gynecology Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Gynecology Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Gynecology Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Distribution Channel

10. South America Gynecology Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics
    • 10.2.2. By Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gynecology Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Gynecology Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Gynecology Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gynecology Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amgen Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Bayer AG
  • 15.4. Merck & Co., Inc.
  • 15.5. Eli Lilly and Company
  • 15.6. Pfizer Inc.
  • 15.7. Abbott Laboratories Inc.
  • 15.8. AbbVie Inc.
  • 15.9. GlaxoSmithKline Plc
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer